title: [Personalized urooncology based on molecular uropathology: what is the future?].
abstract: Targeted therapies and biomarker validation are key drivers in the advancement of personalized oncology which is a growing topic in all clinical areas. Compared with other professions, such as pulmonology and gynecology, development in urology has so far been retarded but has recently gained increasing momentum. A basis for this is the currently growing and in future accelerated application of new knowledge derived from molecular biology in the field of uropathology. The rapid gain of knowledge is driven by a whole new class of analytical methods, such as massively parallel sequencing (deep sequencing or next generation sequencing), which enables analysis of virtually a new universe of potential biomarkers. This article describes the emerging paradigm shift in molecular pathological diagnostics of urological tumors using the example of prostate cancer.
authors.affiliation: Lehr- und Forschungsgebiet Tumorpathologie, Institut für Pathologie, Uniklinik RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Deutschland. edahl@ukaachen.de
authors.forename: E
authors.initials: E
authors.lastname: Dahl
authors.forename: F
authors.initials: F
authors.lastname: Haller
mesh_terms: D003950:Diagnostic Techniques, Urological / Q000639:trends*; D005544:Forecasting; D005820:Genetic Testing / Q000639:trends*; D006801:Humans; D057089:Pathology, Molecular / Q000639:trends*; D057285:Precision Medicine / Q000639:trends*; D014565:Urogenital Neoplasms / Q000175:diagnosis* / Q000235:genetics*